July 9, 2012 — Cardionovum GmbH announced it has initiated in vivo testing of its second drug-eluting balloon (DEB) Restore. The company is currently marketing a line of CE-marked paclitaxel-coated DEBs for coronary (Primus) and peripheral (Legflow) applications. Cardionovum is featured in the most recent issue of IN VIVO magazine.
The Restore family of DEBs is novel because of its fast, intense drug-release platform. Restore was developed for the clinically efficient and successful treatment of patients who come back for repeat anti-proliferative treatment of restenosis. Restore’s paclitaxel coating ensures a biocompatible drug transfer into the arterial tissue under avoidance of micro emboli, which are often observed after application of other DEBs.
“Our core competence is in medical coating technologies. Our mission is to develop an entirely new paradigm for the safest and clinically most effective local drug delivery to the arterial lesion site,” said Michael Orlowski, Ph.D., CEO of Cardionovum. “We believe that our novel approach to drug-coating is superior to existing products on the market, as we do not use plasticizer, nor uncontrollable toxic drug excipients, giving us a potentially dominant position in the emerging market for DEBs as first-line therapy for a wide variety of patients in need of coronary and peripheral vascular interventions.”
Cardionovum’s products are not available for sale in the United States.
For more information: www.cardionovum.eu
April 24, 2024 
